PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2983990-2	1985	In partially purified receptor preparations from eight different tissues insulin best stimulated (highest V) phosphorylation of a random copolymer composed of glutamic and tyrosine residues at a 4:1 ratio (Glu/Tyr, 4:1).	copolymer	137-146	insulin	Homo sapiens	73-80	
27427584-2	2016	In this study, a well-defined block copolymer synthesized via ATRP, i.e., poly(ethylene glycol)-b-poly(2-diisopropylaminoethyl methacrylate) (PEG-b-PDPA), has been used to investigate the insulin release behavior in response to glucose changes for potential diabetes mellitus (DM) therapy.	copolymer	36-45	insulin	Homo sapiens	188-195	
33012880-7	2020	Hydrolytic degradation analysis showed rapid degradation of copolymer in formulation containing higher chain length of CS (200 kDa)-zinc-insulin complexes, implying formation of bigger pores and channels in copolymeric matrix during initial release in this system.	copolymer	60-69	insulin	Homo sapiens	137-144	
21268025-2	2011	A sufficient glucose sensitivity of the copolymer was accomplished by the glucose-induced volume changes of the nanoparticles and release profiles of insulin in phosphate buffered saline (PBS, pH 7.4) with different glucose concentrations, which occurred in a remarkable glucose concentration-dependent manner.	copolymer	40-49	insulin	Homo sapiens	150-157	
24460175-7	2014	The controlled release of insulin from the hydrogel devices was demonstrated by degradation of the copolymer, which is modulated via the 2,2"-dithiodiethanol content in the poly(ether-urethane)s.	copolymer	99-108	insulin	Homo sapiens	26-33	
22203325-0	2012	Protected graft copolymer (PGC) basal formulation of insulin as potentially safer alternative to Lantus  (insulin-glargine): a streptozotocin-induced, diabetic Sprague Dawley rats study.	copolymer	16-25	insulin	Homo sapiens	53-60	
22203325-2	2012	METHODS: Development of protected graft copolymer (PGC) excipients that bind native human insulin non-covalently and testing blood glucose control obtained with these formulations in streptozotocin-induced diabetic Sprague Dawley rats compared to equally dosed insulin glargine.	copolymer	40-49	insulin	Homo sapiens	90-97	
22095295-0	2012	Controlled delivery of basal level of insulin from chitosan-zinc-insulin-complex-loaded thermosensitive copolymer.	copolymer	104-113	insulin	Homo sapiens	38-45	
22095295-0	2012	Controlled delivery of basal level of insulin from chitosan-zinc-insulin-complex-loaded thermosensitive copolymer.	copolymer	104-113	insulin	Homo sapiens	65-72	
24055698-8	2013	Drug release studies showed that the increasing content of MAA in the copolymer enhances release in SIF to design and improve insulin release behavior from these carriers.	copolymer	70-79	insulin	Homo sapiens	126-133	
10210724-9	1999	Leakage rate of insulin from copolymer containing between 7 and 39% by weight of PEG were similar.	copolymer	29-38	insulin	Homo sapiens	16-23	
17629639-7	2007	The insulin and BVP released from the copolymer hydrogel over 15 and 40 days, respectively.	copolymer	38-47	insulin	Homo sapiens	4-11	
21736523-2	2011	The in vitro experiments performed on insulin-loaded microparticles in pH 1.2 media (stomach condition) demonstrated no release of insulin in the first 2 h, but almost 100% insulin was released in pH 7.4 media (intestinal condition) in 6 h. The carrier was characterized by Fourier transform infrared, differential scanning calorimeter, thermogravimetry and nuclear magnetic resonance techniques to confirm the formation of copolymer, while scanning electron microscopy was used to assess the morphology of hydrogel microparticles.	copolymer	424-433	insulin	Homo sapiens	38-45